Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males

What Was Tested

Researchers studied Exenatide in this clinical trial publication.

The researchers explored the mechanisms underlying this potential safety concern.

Who Took Part

According to the abstract, 2 patients were involved.

By PubMed's age tags, the people studied were young adults and adults, men only.

Ten healthy overweight males (aged 20-27 years) were examined in an open label, crossover study.

How the Study Was Run

The design is described as open-label, placebo-controlled and crossover.

Nothing was hidden in this open-label Exenatide study: the patients and staff both knew the treatment.

The comparison arm used a placebo, so changes seen with Exenatide could be set against what happens without it.

Each person switched between Exenatide and the comparison at some point, usually with a gap in between.

Sympathetic nervous system (SNS) activity was measured by heart rate variability and rate-pressure product.

What Was Measured

The subject headings attached to it are Blood Glucose, Body Mass Index, Exenatide, Glucagon-Like Peptide 1, Healthy Volunteers, Heart Rate and Lipids.

Author keywords: GLP-1 receptor agonist, haemodynamics and sympathetic nervous system activity.

What This Means in Plain Language

The paper is an open-label, placebo-controlled and crossover study of Exenatide in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2016 (British journal of clinical pharmacology), a journal based in England.

More context: the Exenatide compound page, all human trials.